Introduction {#s1}
============

Effective bench-to-bedside clinical translation of cellular therapies requires careful understanding of cell fate through tracking. Tracking cells is important to measure (a) cell retention so that delivery methods/cell dose can be optimized and (b) biodistribution and clearance to define potential off-target toxicity and redosing strategies \[[@B1]\]. Unfortunately, cell tracking technology has been hampered by low sensitivity imaging incapable of detecting individual cells and lack of robust imaging labels to detect cells for longer than just the short term \[[@B2]\].

Several cell tracking methods have previously been described, each with certain pitfalls. Magnetic resonance imaging (MRI) can acutely visualize cells labeled with superparamagnetic iron oxide (SPION) or paramagnetic particles with a detection limit of approximately 1 × 10^4^ cells \[[@B3]--[@B8]\]. The uptake of SPION by resident tissue macrophages tends to overestimate cell retention \[[@B9]--[@B11]\]. Positron emission tomography (PET) imaging can visualize radioactive markers such as \[^18^F\]fluorodeoxyglucose (^18^F-FDG) \[[@B12], [@B13]\]. Common radioactive labels such as ^18^F-FDG have relatively short half-lives, limiting the tracking window to 10 hours postlabeling \[[@B14]\]. PET imaging has a detection limit of approximately 1 × 10^4^ cells \[[@B15]\]. Single-photon emission computed tomography (SPECT) requires a radioactive label such as ^111^indium oxine. ^111^Indium oxine has a longer half-life than ^18^F-FDG, allowing imaging for up to 4 days postlabeling \[[@B14]\]. However, SPECT is less sensitive than PET, with a limit of detection of approximately 1 × 10^5^ cells \[[@B3]\]. Bioluminescence is an imaging method that detects light produced from a chemical reaction between an enzyme, such as luciferase, and its substrate, such as luciferin. To achieve this, cells are modified to express reporter genes such as *D-Luciferase*. Bioluminescence can be used to detect transplanted cells over time in vivo but is limited to studies in small animals because of high tissue absorption of emitted light \[[@B16]\]. Bioluminescence offers low-resolution two-dimensional images that must be coregistered to an anatomical reference image for context. The limit of cell detection with this method is approximately 1 × 10^3^ cells \[[@B3]\].

Alternatively, fluorescence microscopy is an imaging method in which an emission light source of a specific wavelength causes dyes to fluoresce at different, yet predictable and detectable, wavelengths. Dyes such as quantum dots (Qdots, CellTracker) or reporter genes such as green fluorescence protein are introduced within the cells before transplantation. Although fluorescence microscopy is currently limited to ex vivo analyses, a major advantage is that it offers high-resolution imaging of single cells within intact tissues or whole animals. Furthermore, three-dimensional (3D) whole-organ fluorescence microscopy has been described \[[@B17]--[@B19]\].

Fluorescence microscopy using Qdots has been tested in a variety of cell types, including mesenchymal stem cells (MSCs) \[[@B20]--[@B22]\], embryonic stem cells \[[@B15], [@B23]\], pancreatic stem cells \[[@B24]\], and neural stem cells \[[@B25]\]. Qdots do not appear to adversely affect cell function and have minimal passive transfer to neighboring cells (\<4%) in mixed culture or host tissues \[[@B21], [@B23], [@B26]\]. However, the detection window for Qdots varies greatly in the literature and is likely related to the cell type being tracked, the cell delivery method, and the disease model being studied.

Our group is interested in testing the safety and therapeutic efficacy of intravenous infusion of MSCs to alleviate or slow the progression of bronchiolitis obliterans (BO) lung injury, which is a serious complication of lung transplantation. To this end, we have filed an investigational new drug (IND) application with the Food and Drug Administration (FDA) to test allogeneic MSC therapy to mitigate BO after lung transplantation. At the request of the FDA, we developed a preclinical model of BO \[[@B27]\] and a method to track MSCs and assess their biodistribution in this lung injury model. After discussion with the FDA panel and consideration of other models, bleomycin was determined to be the most representative and practical model to induce pathology similar to BO. Therefore, we exploited 3D fluorescence cryo-imaging microscopy with Qdot MSC labeling to measure retention and biodistribution in this relevant preclinical lung injury model.

Methods {#s2}
=======

Briefly, Qdot-labeled human MSCs (hMSCs) were infused intravenously in rats after the induction of a lung injury model previously described by our group \[[@B27]\]. Cell retention and biodistribution were measured over time. Details are described below.

MSC Production {#s3}
--------------

The MSCs for these studies were produced by Waisman Biomanufacturing (Madison, WI, <http://gmpbio.com>) using a process that is comparable to that used for cGMP production of bone marrow (BM)-MSCs for human clinical trials \[[@B28]\]. A master cell bank was established at passage 2 using BM derived from a healthy donor. The BM harvest and consenting procedure were performed according to an institutional review board-approved protocol. Medical history was taken, and infectious disease testing was performed on the donor to comply with FDA Donor Eligibility requirements. MSCs were grown in media consisting of α-minimal essential medium with 10% fetal bovine serum and 1× Glutamax. Passaging was performed with TrypLE. The final MSC product was obtained by expanding MSCs from the passage 2 master cell bank to passage 5 in Cell Factories (Nunc). The final MSCs were tested for sterility (no contamination), endotoxins (\<0.5 EU/ml), viability (\>83% post-thaw), identity/purity (standard flow cytometry for MSC markers), and potency (immunopotency assay) as described \[[@B28]\]. MSCs were cryopreserved in a solution consisting of PlasmaLyte A (PL-A) with 2.5% dimethylsulfoxide and 10% human serum albumin and stored in the vapor phase of liquid nitrogen until used for these studies.

Rat Lung Injury Model {#s4}
---------------------

All animal procedures, including euthanasia methods, were approved by the institutional Animal Care and Use Committee. The double-dose bleomycin lung injury model was induced as recently described by our group \[[@B27]\]. Briefly, Sprague-Dawley Rats (*n* = 12) were anesthetized with 5% isoflurane and intubated, and an aerosol delivery device (MicroSprayer Aerosolizer; Penn Century, Wyndmoor, PA, <http://penncentury.com>) was inserted into the trachea. Normal sterile saline (200 μl) containing bleomycin (1.5 U/kg) was then delivered to both lungs. Animals received two doses of bleomycin administered 4 days apart ([Fig. 1](#F1){ref-type="fig"}). Sham control animals (*n* = 3) received no aerosolized solution and were included at the request of the FDA.

![Schematic of the study design. Animals were treated with bleomycin 4 days apart (days −8 and −4). On day 0, all animals received an intravenous infusion of human mesenchymal stem cells (hMSCs) loaded with QT655. On the day of assigned long-term tissue collection (day 2, 4, or 8) each animal received a second dose of hMSCs loaded with QT605. Animals were then euthanized at 60, 120, or 240 minutes after the infusion of QT605. Each group contains three animals for each time point except for the control animals, which had one animal at each time point. Abbreviations: d, day; MSC, mesenchymal stem cell.](sctm_20150379_f1){#F1}

Study Design {#s5}
------------

After induction of the lung injury model and 4 days after the second dose of bleomycin, rats were randomly assigned to receive two infusions of Qdot-labeled hMSCs. The first hMSC infusion was given on day 0 (4 days after the second bleomycin dose). These cells were labeled with QTracker 655 (QT655) to track cells at day 2, 4, or 8 ([Fig. 1](#F1){ref-type="fig"}). The second hMSC infusion was given on day 2, 4, or 8. These cells were labeled with QTracker 605 (QT605) to track cells at 60, 120, and 240 minutes after infusion, and before the animals were euthanized and tissues were collected. Using the two different QTracker reporter wavelengths (655 and 605 nm), each rat was used to examine late, longer-term hMSC distribution (2, 4, or 8 days) and acute, early distribution (60, 120, or 240 minutes) ([Fig. 1](#F1){ref-type="fig"}).

Cell Labeling Procedure {#s6}
-----------------------

One-half milliliter of 6 × 10^6^ hMSCs/ml was removed from liquid nitrogen storage and rapidly thawed in a 37°C water bath. hMSCs were washed twice by suspending in 5.5 ml PL-A and centrifuged at 1,000*g* for 10 minutes at 4°C. QTracker staining was carried out according to the manufacturer's instructions. Briefly, in a 1.5-ml tube, 3 μl reagent A was mixed with 3 μl reagent B (605 or 655), 600 μl PL-A was added, and the mixture was vortexed for 30 seconds. Immediately after the second washing, hMSCs were suspended in 300 μl PL-A, added to the CellTracker labeling solution, and incubated at 37°C for 55 minutes in the dark. After incubation, 600 μl PL-A was added to the cell suspension and centrifuged at 1,000*g* for 10 minutes at 4°C. The labeled hMSCs were then suspended in 1.5 ml PL-A and centrifuged at 1,000*g* for 10 minutes at 4°C. The Qdot-labeled hMSCs were split into two tubes each containing 1.2 × 10^6^ cells and suspended in a volume of 1.3 ml PL-A. Cell viability was calculated before loading the cells for injection. A 25G needle was used to load the cells into a 3-ml syringe for infusion. hMSCs were held on ice in the dark until infused.

Cell Infusion Procedure {#s7}
-----------------------

Rats were anesthetized with 5% isoflurane and maintained at 2% throughout the infusion procedure. An incision on the right anterior side of the neck was made, and the jugular vein was exposed. A butterfly catheter prefilled with the appropriate cell solution was inserted into the vein, and the MSC solution was infused at a rate of 2.2 ml/hour (37 µl/minute). The syringe pump was inverted to prevent cells from settling against the syringe plunger. After infusion of 1.3 ml cell suspension, the infusion line was flushed with 0.5--0.7 ml saline, for a total infusion volume of 1.8--2 ml. Pressure was applied to the vein to stop bleeding, and the skin was closed. The left jugular vein was used for the second hMSC infusion according to the same procedure.

Necropsy and Whole-Organ Imaging {#s8}
--------------------------------

Upon sacrifice, the following organs were removed intact: lung, liver, spleen, kidney, heart, testis, and a portion of small intestine. The lungs, liver, spleen, heart, right kidney, right testis, and a section of the small intestine were frozen and stored (BioInVision, Cleveland, OH, <http://www.bioinvision.com>). Briefly, organs were placed in cryo-imaging embedding compound, frozen in liquid nitrogen vapor, and stored at −80°C until imaging. Whole-organ analysis was performed by serial sectioning and imaging of organs using the CryoViz cryo-imaging system (BioInVision). Section thickness was set to 40 µm, with an in-plane pixel size of 10.232 µm using an Olympus MVX-10 1× objective and ×0.63 magnification. Biodistribution of cells (CT605- and CT655-labeled hMSCs) was analyzed by coregistration of bright field and confocal images to generate a 3D whole-organ image reconstruction. Organs in which \<200 cells were detected using automated detection were manually verified for accuracy.

A positive control was used to validate the dual-labeling technique and ensure spectral separation between first and second hMSC doses. To perform this validation, a healthy animal was euthanized, and the lungs were immediately excised. hMSCs (1 × 10^5^) were labeled with QT605 or QT655, and a 50/50 mix (5.0 × 10^4^ QT605 and 5.0 × 10^4^ QT655) was directly injected into discrete lobes of the freshly excised lung. Immediately after injection into the lungs, the tissue was frozen and submitted for automated cell quantification. This tissue served as both positive and negative control, as cells were located in discrete areas, resulting in most sections being devoid of hMSCs (negative control).

Statistical Analysis {#s9}
--------------------

Data are presented as mean ± SEM. Student's *t* test was used to determine statistical differences between control animals and bleomycin-treated animals. *p* values less than .05 were considered statistically significant.

Results {#s10}
=======

Gross Necropsy {#s11}
--------------

Animals treated with bleomycin had hemorrhagic areas throughout the lungs, but no other abnormalities were observed in other organs. Body weight and organ weights were not different between groups.

Cell Retention {#s12}
--------------

### Validation of Cell Retention in Excised Healthy Lung {#s13}

Detection algorithms developed by BioInvision detected 88,607 of 100,000 QT605-labeled hMSCs, 72,000 of 100,000 QT655-labeled hMSCs, and 65,000 of 100,000 hMSCs in the QT605/QT655 lobe comprising 29,000 hMSC QT605-labeled and 36,000 QT655-labeled hMSCs. Because of suboptimal cutting, the lobes encompassing the QT655 and QT605/QT655 mix of hMSCs experienced debris on the surface of the tissue blocks. We estimated that 15% of cells were lost as a result of leakage of cells from the needle tract and within the dead space between the needle and syringe connection dead space.

### Viability and In Vivo Cell Retention in Organs {#s14}

Mean hMSC viability after thawing and QTracker labeling was 68% (±3%), resulting in an average infusion of 6.46 × 10^5^ (±0.386) viable hMSCs at each time point. Mean total cell retention detected in organs at 60 minutes was 82.0% (±9.7%) and decreased to 60.0% (±17.6%) at 120 minutes and 66.0% (±22.7%) at 240 minutes ([Fig. 2](#F2){ref-type="fig"}). By day 2 postinfusion, cell retention detected in organs fell to 0.06% of total viable hMSCs infused and remained constant until day 8.

![Overall human mesenchymal stem cell (hMSC) retention at short- and long-term time points. Short-term (60, 120, and 240 minutes after infusion) and long-term (2, 4, and 8 days after cell infusion) cell retention in all organs collected after an IV infusion of hMSCs. Data are presented as mean ± SEM of the percentage of cells detected in the tissue that was collected versus the total number of viable cells infused.](sctm_20150379_f2){#F2}

Biodistribution {#s15}
---------------

### Early Biodistribution {#s16}

At 60, 120, and 240 minutes postinfusion, 99.7% of the total cells detected were found in the liver, lungs, and spleen, with the remaining 0.3% of cells distributed in the kidney, heart, intestines, and testis ([Figs. 3A](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}). Cell retention was consistently highest in the liver at 60, 120, and 240 minutes postinfusion, at 77.8% (±4.7%), 85.9% (±2.4%), and 90.2% (±7.0%), respectively. The lungs had the second highest cell retention rate at 60, 120, and 240 minutes, with 20.0% (±4.7%) 10.5% (±2.3%), and 7.6% (±6.5%) respectively. Finally, cell retention in the spleen was 2.0% (±0.4%), 3.3% (±0.1%), and 1.9% (±0.6%) at 60, 120, and 240 minutes postinfusion respectively. Intraorgan cellular biodistribution was uniform within the tissue ([Fig. 5](#F5){ref-type="fig"}) ([supplemental online Videos 1--3](http://stemcellstm.alphamedpress.org/lookup/suppl/doi:10.5966/sctm.2015-0379/-/DC1)).

![Biodistribution of human mesenchymal stem cells (hMSCs) at early and late time points. The total number of cells detected at each time point is represented as percentage of cells by location after an IV infusion of labeled hMSCs infused at 60, 120, and 240 minutes (early biodistribution) **(A)** and 2, 4, and 8 days (late biodistribution) **(B)**. Data are presented as mean ± SEM.](sctm_20150379_f3){#F3}

![Representative fluorescence images with overlaid detected cells for different organs, along with zoomed-in views. **(A):** Lungs; yellow circles represent detected human mesenchymal stem cells (hMSCs). **(B):** Magnified image from red box in A. **(C):** Liver; yellow circles represent detected hMSCs. **(D):** Magnified image from red box in C. **(E):** Spleen; yellow circles represent detected hMSCs. **(F):** Magnified image from red box in E.](sctm_20150379_f4){#F4}

![Intraorgan cellular biodistribution 60 minutes postinfusion. **(A):** 3D bright field reconstruction of lungs. **(B):** 3D bright field reconstruction with an overlay of detected mesenchymal stem cells (MSCs) from fluorescence. **(C):** 3D reconstruction showing detected MSCs from fluorescence.](sctm_20150379_f5){#F5}

### Late Biodistribution {#s17}

The number of cells detected at 2, 4, and 8 days (*n* = 3 per time point) was less than 0.06% of the total cells infused on day 0. The mean number of cells detected in all tissues at day 2, 4, and 8 postinfusion was 361 (±120), 509 (±118) and 422 (±76), respectively. Of the cells detected on day 2, 19.2% ± 4.9% (60 ± 13 cells) were detected in the lungs, 31.5% ± 2.9% (112 ± 39 cells) in the liver, and 33.4% ± 12.1% (140 ± 63 cells) in the spleen. The remaining cells were variably distributed in the kidney (1.9% ± 0.7% \[11 ± 1 cells\]), heart (5.9% ± 1.5% \[19 ± 6 cells\]), intestines (1.4% ± 0.9% \[6 ± 5 cells\]), and testis (4.6% ± 1.8% \[13 ± 2 cells\]) ([Figs. 3B](#F3){ref-type="fig"}, [6](#F6){ref-type="fig"}). Of the cells detected on day 4, 30.2% ± 14.0% (177 ± 108 cells) were detected in the lungs, 22.1% ± 3.0% (106 ± 17 cells) in the liver, and 29.9% ± 14.0% (141 ± 83 cells) in the spleen. The remaining cells were variably distributed in the kidney (1.4% ± 0.6% \[6 ± 2 cells\]), heart (2.4% ± 1.6% \[14 ± 12 cells\]), intestines (9.6% ± 4.2% \[41 ± 10 cells\]), and testis (4.5% ± 1.6% \[24 ± 12 cells\]). Of the cells detected on day 8, 22.8% ± 0.4% (97 ± 18 cells) were detected in the lungs, 22.6% ± 1.9% (93 ± 8 cells) in the liver, and 28.0% ± 13.1% (136 ± 82 cells) in the spleen. The remaining cells were variably distributed in the kidney (5.1% ± 2.1% \[18 ± 6 cells\]), heart (9.3% ± 4.4% \[33 ± 15 cells\]), intestines (2.9% ± 1.3% \[12 ± 5 cells\]), and testis (9.3% ± 4.7% \[34 ± 15 cells\]) ([Fig. 6](#F6){ref-type="fig"}).

![Representative fluorescence images with overlaid detected cells for different organs, along with zoomed-in views. **(A):** Heart; yellow circles represent detected human mesenchymal stem cells (hMSCs). **(B):** Magnified image from red box in A. **(C):** Kidney; yellow circles represent detected hMSCs. **(D):** Magnified image from red box in C.](sctm_20150379_f6){#F6}

### Early Lung Retention in Healthy and Diseased Lungs {#s18}

We compared the retention of hMSCs in the lungs of healthy control rats at 60, 90, and 120 minutes to that of the bleomycin-treated rats at the same time points. Cell retention was numerically higher in the injured lungs (12.7% ± 2.0%, *n* = 9) compared with the healthy lungs (6.4% ± 3.0%, *n* = 3), although the difference was not statistically significant (*p* = .27) ([Fig. 7](#F7){ref-type="fig"}).

![Percentage of cell retention at an early biodistribution (60, 120, and 240 minutes) in the lungs of healthy rats or those treated with two doses of bleomycin. Data presented as mean ± SEM (*p* = .27).](sctm_20150379_f7){#F7}

Discussion {#s19}
==========

To our knowledge, this is the first study to use 3D whole-organ cryo-imaging to track intravenously infused hMSCs in an acute rat lung injury model. A motivation behind this study was to measure cell biodistribution to support an FDA IND to permit clinical trials of MSCs for transplant-associated bronchiolitis obliterans. 3D whole-organ cryo-imaging is a sensitive method that provides accurate retention, biodistribution, and clearance information for infused hMSCs. Loading hMSCs with quantum dots of two distinct wavelengths (605 and 655 nm) allowed for acute and longer-term cell tracking within the same animal. Eighty percent of the infused labeled cells were detected within six organs at 1 hour postinfusion, falling to \<0.06% by day 2 postinfusion. The ultrasensitive nature of 3D cryo-imaging allowed for single-cell detection in all organs tested ([Figs. 4](#F4){ref-type="fig"}, [6](#F6){ref-type="fig"}). Organs were serially sectioned at 40 μm, significantly reducing sampling bias compared with other microscopy-based cell quantification techniques. Additionally, the Qdot wavelengths (605 and 655 nm) were specifically chosen to fall outside the range of typical tissue autofluorescence to reduce the likelihood of false discovery. Detection of 100% of the cell preparation is not expected, as cells are lost to priming of the delivery catheter, dead spaces in the syringe and fittings of the delivery system, as well as during placement of the catheter in the jugular vein. Additionally, because of sample size limitations, our cell tracking efforts were limited to a subset of selected organs. It is likely that a small percentage of infused MSCs are retained in the circulatory system and skeletal musculature and thus excluded from biodistribution and quantification analysis. For these reasons, biodistribution was calculated as a percentage of the total cells detected at each time point and not from the actual total number of cells delivered.

After intravenous infusion, hMSCs were primarily localized to the lungs, liver, and spleen, a finding that is similar to previous reports \[[@B29]--[@B32]\]. However, in our study, cell retention was highest in the liver, which is not consistent with previous reports that found higher acute cell retention in lungs \[[@B29], [@B30], [@B33]--[@B38]\]. For example, Fischer et al. found that nearly 99% of rat MSCs administered by intravenous infusion were initially retained in the lungs in a nondiseased rat model \[[@B29]\]. Similarly, in a mouse model of emphysema, Kim et al. showed that human adipose-derived MSCs were primarily retained in the lungs at 1 and 4 hours after intravenous infusion, which was further increased by the induction of emphysema \[[@B33]\]. This discrepant result may be caused by the differences in measurement time intervals, animal models, cell types, and cell-tracking methods. For example, studies using bioluminescence to track cells underestimate cell retention in the liver because of its high tissue absorption coefficient \[[@B39]\]. The increased liver tissue density results in greater light absorption compared with the lungs. Virostko et al. demonstrated that bioluminescence cell quantification is susceptible to changes/differences animal positioning, postsurgical effects, and light attenuation as a function of transplant site \[[@B40]\]. Changes in these variables may lead to an overestimation of cell retention in the lungs compared with the liver. Finally, PET and SPECT cell quantification is subject to multiple variables that may impact quantification accuracy, specifically, nonspecific uptake of radiolabels in the musculoskeletal system and artifacts related to inflammation, which may impact cell quantification accuracy \[[@B41], [@B42]\].

3D cryo-imaging offers single-cell sensitivity, which allows for accurate quantification and assessment of 3D biodistribution of infused cells. In contrast, PET, SPECT, MRI, or bioluminescence/fluorescence imaging modalities are considerably less sensitive than 3D cryo-imaging \[[@B3]\]. Interestingly, the presence of lung injury did not significantly boost cell retention in the lungs compared with healthy controls.

There are several limitations to this study. First, we used xenotransplantation of hMSCs into an immunocompetent rat lung injury model. Although several studies suggest that MSCs are immunoprivileged because of the relatively low expression of MHC class II and other and costimulatory proteins \[[@B43]--[@B47]\], there is the potential that an immune response could still be elicited. This is especially true when administering multiple MSCs doses, which could result in priming the immune system to target the second cell dose for clearance \[[@B48], [@B49]\]. We did not observe significant reductions in hMSCs between 60 and 240 minutes postinfusion, which would suggest that no significant immune system priming occurs in that short period of time. Second, the influence of quantum dot labeling on cell survival, proliferation, migration, or differentiation was not determined in this study. Previous Qdot labeling studies have not shown impaired survival, proliferation, migration or differentiation \[[@B15], [@B20]--[@B23]\]. Third, although Qdot dilution caused by cell division has not been shown to be a major component of the loss of Qdot signal over time \[[@B24], [@B50]\], we cannot rule out the potential loss of Qdot signal caused by MSC proliferation. Finally, we only tested MSCs and therefore, these findings may not be extended to other cell types.

Conclusion {#s20}
==========

3D cryo-imaging can be used to track single MSCs across a range of organs. Intravenous infusion of hMSCs in a rat lung injury model results in acute retention of cells primarily in the liver, lungs, and spleen, with few cells detected in the heart, kidney, intestine, or testis. hMSC retention is greatly reduced by 2 days postinfusion and remains relatively constant up to 8 days postinfusion. In our model, lung injury does not result in an increase in acute lung retention of infused hMSCs compared with normal uninjured lungs.
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